AnaptysBio has reported that the ARISE-AD trial of its investigational B and T lymphocyte attenuator (BTLA) agonist, ANB032, ...

ANB032 was well tolerated across all doses with no safety signals observedAD trial and all further investment in ANB032 will be ...

AnaptysBio, Inc. (NASDAQ:ANAB) announced that investigational ANB032, a BTLA agonist, did not meet the primary and secondary ...

Phase IIb study on ANAB's ANB032 for atopic dermatitis fails to meet goals. The company decides to discontinue any further investment in the candidate.

AnaptysBio is dropping its atopic dermatitis (AD) drug candidate after the compound failed to reduce eczema area and itch ...

San Diego, USA-based biotech AnaptysBio today announced that investigational ANB032, a BTLA agonist, did not meet the primary ...

AnaptysBio (ANAB) announced that investigational ANB032, a BTLA agonist, did not meet the primary and secondary endpoints in any of the doses ...

Its most advanced project is MB272, an agonist of B- and T-lymphocyte attenuator (BTLA) which recently started phase 1 testing, and it has a PD-1 agonist called MB151 in late preclinical development.

The rebel leader who helped oust the Assad regime calls on countries to hand over “criminals” who fled Syria. A new caretaker prime minister warns that the country faces a dire financial ...

Dec. 5, 2024 — The fungus that causes coffee wilt disease repeatedly took up segments of DNA from a related fungal pathogen, which contributed to successive ... Single Mutation in H5N1 Influenza ...

Dec. 9, 2024 — Researchers found that adolescents with more symptoms of gaming addiction showed lower brain activity in the region involved in decision-making and reward processing; this blunted ...